Neurokinin-1 receptors are decreased in major depressive disorder

Craig A. Stockmeier*, Xiaochun Shi, Lisa Konick, James C. Overholser, George Jurjus, Herbert Y. Meltzer, Lee Friedman, Pierre Blier, Grazyna Rajkowska

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Treatment with an antagonist at the neurokinin-I (NK-1) receptor may alleviate depression, however the brain region(s) in which the NK-1 receptor antagonist exerts its therapeutic effect is unknown. [1251]BH-Substance P was used to measure NK-1 receptors postmortem in cytoarchitectonically defined areas of rostral orbitofrontal cortex (Brodmann's area 47) of subjects with major depressive disorder (n = 12, six females) and psychiatrically normal subjects (n = 11, five females). Six subjects with depression died by suicide. Subjects with depression showed decreased binding to NK-1 receptors across all cortical layers (p = 0.024). The pathophysiology of depression, and the reported therapeutic benefit of NK-1 receptor antagonists, may thus involve NK-1 receptors in prefrontal cortex.

Original languageEnglish (US)
Pages (from-to)1223-1227
Number of pages5
Issue number9
StatePublished - Jul 2 2002


  • Depression
  • Neurokinin-1 receptor
  • Orbitofrontal cortex
  • Postmortem

ASJC Scopus subject areas

  • General Neuroscience


Dive into the research topics of 'Neurokinin-1 receptors are decreased in major depressive disorder'. Together they form a unique fingerprint.

Cite this